Liver-selective γ-secretase inhibition ameliorated diet-induced dyslipidaemia in mice [55], indicating that targeting the γ-secretase cleavage of the LDLR could provide an alternative therapeutic approach to treat hypercholesterolemia. The gene discussed is LDLR; the disease is Hypercholesterolemia.